- Home
- TCRT vs SHPH Comparison
TCRT vs SHPH Comparison
Compare TCRT & SHPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCRT
- SHPH
- Stock Information
- Founded
- TCRT 1998
- SHPH 2012
- Country
- TCRT United States
- SHPH United States
- Employees
- TCRT N/A
- SHPH N/A
- Industry
- TCRT Biotechnology: Pharmaceutical Preparations
- SHPH Biotechnology: Pharmaceutical Preparations
- Sector
- TCRT Health Care
- SHPH Health Care
- Exchange
- TCRT Nasdaq
- SHPH Nasdaq
- Market Cap
- TCRT 3.8M
- SHPH 2.3M
- IPO Year
- TCRT N/A
- SHPH 2022
- Fundamental
- Price
- TCRT $3.01
- SHPH $0.27
- Analyst Decision
- TCRT
- SHPH
- Analyst Count
- TCRT 0
- SHPH 0
- Target Price
- TCRT N/A
- SHPH N/A
- AVG Volume (30 Days)
- TCRT 49.8K
- SHPH 1.9M
- Earning Date
- TCRT 05-19-2025
- SHPH 05-16-2025
- Dividend Yield
- TCRT N/A
- SHPH N/A
- EPS Growth
- TCRT N/A
- SHPH N/A
- EPS
- TCRT N/A
- SHPH N/A
- Revenue
- TCRT $10,000.00
- SHPH N/A
- Revenue This Year
- TCRT $5,680,500.00
- SHPH N/A
- Revenue Next Year
- TCRT N/A
- SHPH N/A
- P/E Ratio
- TCRT N/A
- SHPH N/A
- Revenue Growth
- TCRT 100.00
- SHPH N/A
- 52 Week Low
- TCRT $1.31
- SHPH $0.23
- 52 Week High
- TCRT $14.20
- SHPH $4.71
- Technical
- Relative Strength Index (RSI)
- TCRT 60.22
- SHPH 38.01
- Support Level
- TCRT $2.56
- SHPH $0.25
- Resistance Level
- TCRT $2.91
- SHPH $0.32
- Average True Range (ATR)
- TCRT 0.28
- SHPH 0.03
- MACD
- TCRT 0.02
- SHPH 0.01
- Stochastic Oscillator
- TCRT 100.00
- SHPH 27.01
About TCRT Alaunos Therapeutics Inc.
Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens arising from genomic mutations. It has a single reportable and operating segment related to biopharmaceutical research and development.
About SHPH Shuttle Pharmaceuticals Holdings Inc.
Shuttle Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company leveraging its proprietary technology to develop novel therapies designed to cure cancers. The company's goal is to extend the benefits of cancer treatments with surgery, radiation therapy, chemotherapy and immunotherapy. Radiation therapy (RT) is one of the effective modalities for treating cancers. It is developing a pipeline of products designed to address the limitations of the current cancer therapies as well as to extend to the new applications of RT. The company believes that its product candidates will enable the company to deliver cancer treatments that are safer, more reliable and at a greater scale than that of the current standard of care.